|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al:
Metastatic non-small-cell lung cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
27(Suppl 5): Sv1–Sv27. 2016. View Article : Google Scholar
|
|
5
|
Ricciuti B, Leonardi GC, Metro G, Grignani
F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A,
Zicari D and Crinò L: Targeting the KRAS variant for treatment of
non-small cell lung cancer: Potential therapeutic applications.
Expert Rev Respir Med. 10:53–68. 2016. View Article : Google Scholar
|
|
6
|
Shajani-Yi Z, de Abreu FB, Peterson JD and
Tsongalis GJ: Frequency of somatic TP53 mutations in combination
with known pathogenic mutations in colon adenocarcinoma, non-small
cell lung carcinoma, and gliomas as identified by next-generation
sequencing. Neoplasia. 20:256–262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Azzoli CG, Baker S Jr, Temin S, Pao W,
Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et
al: American society of clinical oncology clinical practice
guideline update on chemotherapy for stage IV non-small-cell lung
cancer. J Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu WH, Zhao X, Zhu J, Kim IK, Rao G,
McCutcheon J, Hsu ST, Teicher B, Kallakury B, Dowlati A, et al:
Checkpoint kinase 1 inhibition enhances cisplatin cytotoxicity and
overcomes cisplatin resistance in SCLC by promoting mitotic cell
death. J Thorac Oncol. 14:1032–1045. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sarin N, Engel F, Kalayda GV, Mannewitz M,
Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde
U and Frötschl R: Cisplatin resistance in non-small cell lung
cancer cells is associated with an abrogation of cisplatin-induced
G2/M cell cycle arrest. PLoS One. 12:e01810812017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai Y, Yan X, Zhang G, Zhao W and Jiao S:
The predictive value of ERCC1 and p53 for the effect of
panobinostat and cisplatin combination treatment in NSCLC.
Oncotarget. 6:18997–19005. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shtivelman E, Hensing T, Simon GR, Dennis
PA, Otterson GA, Bueno R and Salgia R: Molecular pathways and
therapeutic targets in lung cancer. Oncotarget. 5:1392–1433.
2014.PubMed/NCBI
|
|
13
|
Georgakilas AG, Martin OA and Bonner WM:
P21: A two-faced genome guardian. Trends Mol Med. 23:310–319. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gasperi-Campani A, Roncuzzi L, Ricotti L,
Lenzi L, Gruppioni R, Sensi A, Zini N, Zoli W and Amadori D:
Molecular and biological features of two new human squamous and
adenocarcinoma of the lung cell lines. Cancer Genet Cytogenet.
107:11–20. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pasini A, Paganelli G, Tesei A, Zoli W,
Giordano E and Calistri D: Specific biomarkers are associated with
docetax-eland gemcitabine-resistant NSCLC cell lines. Transl Oncol.
5:461–468. 2012. View Article : Google Scholar
|
|
16
|
Pignatta S, Arienti C, Zoli W, Di Donato
M, Castoria G, Gabucci E, Casadio V, Falconi M, De Giorgi U,
Silvestrini R and Tesei A: Prolonged exposure to (R)-bicalutamide
generates a LNCaP subclone with alteration of mitochondrial genome.
Mol Cell Endocrinol. 382:314–324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar
|
|
19
|
Pasini A, Bonafe F, Govoni M, Guarnieri C,
Morselli PG, Sharma HS, Caldarera CM, Muscari C and Giordano E:
Epigenetic signature of early cardiac regulatory genes in native
human adipose-derived stem cells. Cell Biochem Biophys. 67:255–262.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang K, Chiu CC, Li CH, Chang YT and Hwang
HT: Cisplatin-induced senescence and growth inhibition in human
non-small cell lung cancer cells with ectopic transfer of p16INK4a.
Oncol Res. 16:479–488. 2007. View Article : Google Scholar
|
|
21
|
Kung ML, Hsieh CW, Tai MH, Weng CH, Wu DC,
Wu WJ, Yeh BW, Hsieh SL, Kuo CH, Hung HS and Hsieh S: Nanoscale
characterization illustrates the cisplatin-mediated biomechanical
changes of B16-F10 melanoma cells. Phys Chem Chem Phys.
18:7124–7131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Masters GA, Temin S, Azzoli CG, Giaccone
G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller
JH, et al: Systemic therapy for stage IV non-small-cell lung
cancer: American society of clinical oncology clinical practice
guideline update. J Clin Oncol. 33:3488–3515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kasai D, Ozasa H, Oguri T, Miyazaki M,
Uemura T, Takakuwa O, Kunii E, Ohkubo H, Maeno K and Niimi A:
Thymidylate synthase gene copy number as a predictive marker for
response to pemetrexed treatment of lung adenocarcinoma. Anticancer
Res. 33:1935–1940. 2013.PubMed/NCBI
|
|
24
|
Yoon JY, Park CK, Choi YD, Oh IJ and Kim
YC: Predictive factors for long-term responders of pemetrexed
maintenance treatment in non-small cell lung cancer. Thorac Cancer.
10:942–949. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Friboulet L, Olaussen KA, Pignon JP,
Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour
L, Pirker R, et al: ERCC1 isoform expression and DNA repair in
non-small-cell lung cancer. N Engl J Med. 368:1101–1110. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lord RV, Brabender J, Gandara D, Alberola
V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón
M, et al: Low ERCC1 expression correlates with prolonged survival
after cisplatin plus gemcitabine chemo-therapy in non-small cell
lung cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
|
|
27
|
Vilmar A and Sorensen JB: Excision repair
cross-complementation group 1 (ERCC1) in platinum-based treatment
of non-small cell lung cancer with special emphasis on carboplatin:
A review of current literature. Lung Cancer. 64:131–139. 2009.
View Article : Google Scholar
|
|
28
|
Andriani F, Perego P, Carenini N, Sozzi G
and Roz L: Increased sensitivity to cisplatin in non-small cell
lung cancer cell lines after FHIT gene transfer. Neoplasia. 8:9–17.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cortinovis DL, Andriani F, Livio A, Fabbri
A, Perrone F, Marcomini B, Pilotti S, Mariani L, Bidoli P, Bajetta
E, et al: FHIT and p53 status and response to platinum-based
treatment in advanced non-small cell lung cancer. Curr Cancer Drug
Targets. 8:342–348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu DW, Lee MC, Hsu NY, Wu TC, Wu JY, Wang
YC, Cheng YW, Chen CY and Lee H: FHIT loss confers cisplatin
resistance in lung cancer via the AKT/NF-KB/Slug-mediated PUMA
reduction. Oncogene. 34:3882–3883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harada D, Takigawa N and Kiura K: The role
of STAT3 in non-small cell lung cancer. Cancers (Basel). 6:708–722.
2014. View Article : Google Scholar
|
|
32
|
Hu Y, Hong Y, Xu Y, Liu P, Guo DH and Chen
Y: Inhibition of the JAK/STAT pathway with ruxolitinib overcomes
cisplatin resistance in non-small-cell lung cancer NSCLC.
Apoptosis. 19:1627–1636. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bunz F, Dutriaux A, Lengauer C, Waldman T,
Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B:
Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abbas T and Dutta A: P21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu S, Bishop WR and Liu M: Differential
effects of cell cycle regulatory protein p21(WAF1/Cip1) on
apoptosis and sensitivity to cancer chemotherapy. Drug Resist
Updat. 6:183–195. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karimian A, Ahmadi Y and Yousefi B:
Multiple functions of p21 in cell cycle, apoptosis and
transcriptional regulation after DNA damage. DNA Repair (Amst).
42:63–71. 2016. View Article : Google Scholar
|
|
37
|
Kreis NN, Louwen F and Yuan J: The
multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation,
migration and cancer therapy. Cancers (Basel). 11. pp. E12202019,
View Article : Google Scholar
|
|
38
|
Wu L and Levine AJ: Differential
regulation of the p21/WAF-1 and mdm2 genes after high-dose UV
irradiation: P53-dependent and p53-independent regulation of the
mdm2 gene. Mol Med. 3:441–451. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang K, Zheng XY, Qin J, Wang YB, Bai Y,
Mao QQ, Wan Q, Wu ZM and Xie LP: Up-regulation of p21WAF1/Cip1 by
saRNA induces G1-phase arrest and apoptosis in T24 human bladder
cancer cells. Cancer Lett. 265:206–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cazzalini O, Scovassi AI, Savio M, Stivala
LA and Prosperi E: Multiple roles of the cell cycle inhibitor
p21(CDKN1A) in the DNA damage response. Mutat Res. 704:12–20. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Coqueret O: New roles for p21 and p27
cell-cycle inhibitors: A function for each cell compartment? Trends
Cell Biol. 13:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abella N, Brun S, Calvo M, Tapia O, Weber
JD, Berciano MT, Lafarga M, Bachs O and Agell N: Nucleolar
disruption ensures nuclear accumulation of p21 upon DNA damage.
Traffic. 11:743–755. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shoji T, Tanaka F, Takata T, Yanagihara K,
Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S,
et al: Clinical significance of p21 expression in non-small-cell
lung cancer. J Clin Oncol. 20:3865–3871. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lincet H, Poulain L, Remy JS, Deslandes E,
Duigou F, Gauduchon P and Staedel C: The p21(cip1/waf1)
cyclin-dependent kinase inhibitor enhances the cytotoxic effect of
cisplatin in human ovarian carcinoma cells. Cancer Lett. 161:17–26.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mitsuuchi Y, Johnson SW, Selvakumaran M,
Williams SJ, Hamilton TC and Testa JR: The phosphatidylinositol
3-kinase/AKT signal transduction pathway plays a critical role in
the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and
paclitaxel. Cancer Res. 60:5390–5394. 2000.PubMed/NCBI
|
|
46
|
Rosetti M, Zoli W, Tesei A, Ulivi P,
Fabbri F, Vannini I, Brigliadori G, Granato AM, Amadori D and
Silvestrini R: Iressa strengthens the cytotoxic effect of docetaxel
in NSCLC models that harbor specific molecular characteristics. J
Cell Physiol. 212:710–716. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dabrowska M, Mosieniak G, Skierski J,
Sikora E and Rode W: Methotrexate-induced senescence in human
adenocarcinoma cells is accompanied by induction of p21(waf1/cip1)
expression and lack of polyploidy. Cancer Lett. 284:95–101. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wu MF, Hsiao YM, Huang CF, Huang YH, Yang
WJ, Chan HW, Chang JT and Ko JL: Genetic determinants of pemetrexed
responsiveness and nonresponsiveness in non-small cell lung cancer
cells. J Thorac Oncol. 5:1143–1151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang WY, Yang PM, Chang YF, Marquez VE
and Chen CC: Methotrexate induces apoptosis through
p53/p21-dependent pathway and increases E-cadherin expression
through downregulation of HDAC/EZH2. Biochem Pharmacol. 81:510–517.
2011. View Article : Google Scholar
|
|
50
|
Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W,
De W, Wang Z and Wang R: The long noncoding RNA HOTAIR contributes
to cisplatin resistance of human lung adenocarcinoma cells via
downregualtion of p21(WAF1/CIP1) expression. PLoS One.
8:e772932013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang H, Zhu LJ, Yang YC, Wang ZX and Wang
R: MiR-224 promotes the chemoresistance of human lung
adenocarcinoma cells to cisplatin via regulating G1/S
transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer.
111:339–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Koster R, di Pietro A, Timmer-Bosscha H,
Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA
and de Jong S: Cytoplasmic p21 expression levels determine
cisplatin resistance in human testicular cancer. J Clin Invest.
120:3594–3605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Pasini A, Delmonte A, Tesei A, Calistri D
and Giordano E: Targeting chromatin-mediated transcriptional
control of gene expression in non-small cell lung cancer therapy:
Preclinical rationale and clinical results. Drugs. 75:1757–1771.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH
and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by
akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat
Cell Biol. 3:245–252. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li Y, Dowbenko D and Lasky LA: AKT/PKB
phosphorylation of p21Cip/WAF1 enhances protein stability of
p21Cip/WAF1 and promotes cell survival. J Biol Chem.
277:11352–11361. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Heliez C, Baricault L, Barboule N and
Valette A: Paclitaxel increases p21 synthesis and accumulation of
its AKT- phosphorylated form in the cytoplasm of cancer cells.
Oncogene. 22:3260–3268. 2003. View Article : Google Scholar
|
|
57
|
Perez-Tenorio G, Berglund F, Esguerra
Merca A, Nordenskjöld B, Rutqvist LE, Skoog L and Stål O:
Cytoplasmic p21WAF1/CIP1 correlates with akt activation and poor
response to tamoxifen in breast cancer. Int J Oncol. 28:1031–1042.
2006.PubMed/NCBI
|
|
58
|
Vincent AJ, Ren S, Harris LG, Devine DJ,
Samant RS, Fodstad O and Shevde LA: Cytoplasmic translocation of
p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in
chemoresistance. FEBS Lett. 586:3429–3434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li
K, Fang Y, Weng D, Weng Y, et al: Cytoplasmic p21 is a potential
predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer.
11:3992011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochem Pharmacol. 90:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
